Lava Therapeutics (LVTX) stock price, revenue, and financials

Lava Therapeutics market cap is $176.8 m, and annual revenue was €3.19 m in FY 2020

$176.8 M

LVTX Mkt cap, 20-Oct-2021

€3.2 M

Lava Therapeutics Revenue FY, 2020
Lava Therapeutics Net income (FY, 2020)-13.6 M
Lava Therapeutics EBIT (FY, 2020)-12.8 M
Lava Therapeutics Cash, 31-Dec-202012.9 M
Lava Therapeutics EV167.2 M
Get notified regarding key financial metrics and revenue changes at Lava TherapeuticsLearn more
Banner background

Lava Therapeutics Income Statement

Annual

EURFY, 2019FY, 2020

Revenue

3.2m

R&D expense

7.5m13.6m

General and administrative expense

1.1m2.3m

Operating expense total

8.6m16.0m

EBIT

(8.6m)(12.8m)

EBIT margin, %

(402%)

Interest expense

78.0k294.0k

Pre tax profit

(8.7m)(13.5m)

Income tax expense

35.0k

Net Income

(8.7m)(13.6m)

EPS

(19.4)(34.0)

Lava Therapeutics Balance Sheet

Annual

EURFY, 2019FY, 2020

Cash

6.5m12.9m

Accounts Receivable

61.0k929.0k

Prepaid Expenses

55.0k95.0k

Current Assets

6.8m14.8m

PP&E

654.0k906.0k

Total Assets

7.8m16.7m

Accounts Payable

376.0k760.0k

Short-term debt

229.0k168.0k

Current Liabilities

1.3m5.8m

Long-term debt

1.3m3.2m

Non-Current Liabilities

1.3m4.6m

Total Debt

1.6m3.3m

Total Liabilities

2.6m10.5m

Additional Paid-in Capital

17.1m35.2m

Retained Earnings

(12.2m)(29.4m)

Total Equity

5.2m6.2m

Debt to Equity Ratio

0.3 x0.5 x

Debt to Assets Ratio

0.2 x0.2 x

Financial Leverage

1.5 x2.7 x

Lava Therapeutics Cash Flow

Annual

EURFY, 2019FY, 2020

Net Income

(8.7m)(13.6m)

Depreciation and Amortization

233.0k402.0k

Accounts Receivable

33.0k(868.0k)

Accounts Payable

(169.0k)230.0k

Cash From Operating Activities

(7.7m)(8.5m)

Purchases of PP&E

(724.0k)(437.0k)

Cash From Investing Activities

(750.0k)(437.0k)

Long-term Borrowings

(86.0k)(209.0k)

Cash From Financing Activities

1.0m16.0m

Net Change in Cash

(7.4m)7.1m

Lava Therapeutics Ratios

EURFY, 2019

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.5 x

Lava Therapeutics Operating Metrics

FY, 2020Mar, 2021

Discovery Phase Products

1

Patent Applications (Europe)

4

Patent Applications (Foreign)

17

Patent Applications (US)

2

Patent Cooperation Treaty Applications

4

Patents (Foreign)

4

Patents (US)

2

Preclinical Phase Products

4